• Kymera Therapeutics’ partner Sanofi dosed the first participant in a Phase 1 trial of oral IRAK4 degrader KT-485 (SAR447971).
• No results have been presented; the study is designed to assess safety and drug behavior in healthy volunteers and hidradenitis suppurativa patients.
• The first dose triggered a USD 20 million milestone payment from Sanofi to Kymera under the collaboration.
• Sanofi leads development, regulatory, and commercial work; Kymera remains eligible for up to USD 975 million in further milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090700PRIMZONEFULLFEED9733813) on June 09, 2026, and is solely responsible for the information contained therein.